Alzheimer's Association Salutes Advocate and Mountaineer Now Climbing Everest as Part of The 7 Summits Climb for Alzheimer's
SOUTH SAN FRANCISCO, Calif., May 10, 2011 /PRNewswire/ -- Janssen Alzheimer Immunotherapy, together with its collaborator on the Alzheimer's Immunotherapy Program, Pfizer Inc., is pleased to announce the Alzheimer's Association, the world's leading voluntary health organization in Alzheimer's care, support and research, as a new beneficiary of The 7 Summits Climb for Alzheimer's: Memories are Everything campaign. Through this campaign, mountaineer and Alzheimer's disease advocate Alan Arnette is seeking to climb the 7 Summits, the highest peak on each continent, to raise awareness of the enormous financial and personal burden Alzheimer's places on people with the disease, their family caregivers and society, as well as to raise $1 million for the Alzheimer's community. Alan's highest and most challenging climb of the 7 Summits, Mt. Everest, is now underway.
Everest, the tallest peak in the world, is Alan's third climb of the 7 summits, after he successfully summitted Vinson Massif in Antarctica and Aconcagua in Argentina. Alan is attempting to reach the peaks of all 7 summits in one year, and if successful, will join just a small group of climbers who have accomplished this major feat. He will face challenges climbing Everest, including altitude sickness, hidden crevasses and the Khumbu Icefall a slow moving river of unsteady ice with falling ice towers. Alan's inspiration for his challenging climbs is his mother, Ida Arnette, whom he cared for as she suffered from Alzheimer's, a devastating disease for which there's no cure, and ultimately passed away in 2009. The funds he raises will go directly to three leading nonprofit organizations: the Alzheimer's Association, the Cure Alzheimer's Fund and the National Family Caregivers Association (NFCA).
"We wish Alan the best as he attempts to climb the world's highest mountain for Alzheimer's disease," said Stef Heylen, MD, Chief Medical Officer and Head of Research and Development for Janssen Alzheimer Immunotherapy, on behalf of the Alzheimer's Immunotherapy Program. "We support his year-long effort to call attention to Alzheimer's and the impact it has on families, caregivers and society."
"The Alzheimer's Association sincerely appreciates Alan's support and dedications in raising awareness and supporting our efforts to create a world without Alzheimer's. Alan knows firsthand the devastating impact Alzheimer's has on individuals and their loved ones and represents a generation of baby boomers, too many of whom will spend their retirement years with Alzheimer's or caring for someone who has it," said Angela Geiger, Chief Strategy Officer of the Alzheimer's Association. "It is our hope that Alan's dedication will inspire people to get involved by advocating, donating and educating others about Alzheimer's disease."
Alzheimer's touches the lives of millions of Americans, and according to the Alzheimer's Association, 5.4 million Americans are living with Alzheimer's and require that nearly 15 million people to provide care and support. The Alzheimer's Immunotherapy Program of Janssen Alzheimer Immunotherapy and Pfizer Inc. is funding Alan's climbs so that all money he raises from donations will go directly to the organizations he has selected. You can follow Alan's progress on Everest or make a donation to one of his chosen nonprofits by visiting www.Climb4AD.com or www.Facebook.com/Climb4AD.
Alzheimer's Immunotherapy Program
The Alzheimer's Immunotherapy Program of Janssen Alzheimer Immunotherapy and Pfizer Inc. is an equal collaboration committed to researching and developing selective products for the treatment and/or prevention of neurodegenerative conditions, including Alzheimer's disease.
The Alzheimer's Immunotherapy Program believes that it is possible to reduce the burden of disease through early intervention in the illness. It is dedicated to delivering comprehensive and integrated solutions that help address the needs of people impacted by Alzheimer's disease.
Its research focuses on the beta amyloid hypothesis. Scientific evidence supports the idea that preventing the accumulation and/or promoting the removal of beta-amyloid may have the potential to slow the progression of Alzheimer's disease and help preserve function in people with the disease. This theory is being tested in clinical trials.
Janssen Alzheimer Immunotherapy
Janssen Alzheimer Immunotherapy is researching, developing and commercializing selective products for the treatment and/or prevention of Alzheimer's disease. Janssen Alzheimer Immunotherapy is based in Dublin and has R&D facilities in South San Francisco.
The Alzheimer's Association is the leading voluntary health organization in Alzheimer care, support and research. Our mission is to eliminate Alzheimer's disease through the advancement of research; to provide and enhance care and support for all affected; and to reduce the risk of dementia through the promotion of brain health. Our vision is a world without Alzheimer'sŪ. For more information, visit www.alz.org.
National Family Caregivers Association
National Family Caregivers Association (NFCA) envisions an America in which family caregivers lead full and productive lives, free from depression, pain, isolation, and financial distress. NFCA provides family caregivers support, education, and a public voice.
Cure Alzheimer's Fund
The Cure Alzheimer's Fund is a non-profit public charity established to provide funding for targeted research into the causes of Alzheimer's disease. The Cure Alzheimer's Fund exists exclusively to fund targeted research to hasten the slowing, stopping or reversing of Alzheimer's disease.
SOURCE Janssen Alzheimer Immunotherapy